Serving hundreds of leading biopharmaceutical companies globally:

Generated: October 17, 2018

DrugPatentWatch Database Preview

Mallinckrodt Inc Company Profile

« Back to Dashboard

What is the competitive landscape for MALLINCKRODT INC, and when can generic versions of MALLINCKRODT INC drugs launch?

MALLINCKRODT INC has four approved drugs.

There are thirteen US patents protecting MALLINCKRODT INC drugs.

Summary for Mallinckrodt Inc

US Patents:	13
Tradenames:	4
Ingredients:	4
NDAs:	4
Drug Master File Entries:	67
Patent Litigation for Mallinckrodt Inc:	See patent lawsuits for Mallinckrodt Inc

Drugs and US Patents for Mallinckrodt Inc

+ Get email alerts for changes to this table

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mallinckrodt Inc	XARTEMIS XR	acetaminophen; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	204031-001	Mar 11, 2014		DISCN	Yes	No	8,597,681	➤ Sign Up	Y			➤ Sign Up
Mallinckrodt Inc	METHADONE HYDROCHLORIDE	methadone hydrochloride	POWDER;FOR RX COMPOUNDING	006383-003	Approved Prior to Jan 1, 1982		DISCN	No	No		➤ Sign Up				➤ Sign Up
Mallinckrodt Inc	METHADONE HYDROCHLORIDE	methadone hydrochloride	POWDER;FOR RX COMPOUNDING	006383-002	Approved Prior to Jan 1, 1982		DISCN	No	No		➤ Sign Up				➤ Sign Up
Mallinckrodt Inc	XARTEMIS XR	acetaminophen; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	204031-001	Mar 11, 2014		DISCN	Yes	No	8,668,929	➤ Sign Up				➤ Sign Up
Mallinckrodt Inc	XARTEMIS XR	acetaminophen; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	204031-001	Mar 11, 2014		DISCN	Yes	No	8,372,432	➤ Sign Up	Y			➤ Sign Up
Mallinckrodt Inc	XARTEMIS XR	acetaminophen; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	204031-001	Mar 11, 2014		DISCN	Yes	No	8,377,453	➤ Sign Up	Y			➤ Sign Up
Mallinckrodt Inc	XARTEMIS XR	acetaminophen; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	204031-001	Mar 11, 2014		DISCN	Yes	No	6,488,962	➤ Sign Up	Y			➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Paragraph IV (Patent) Challenges for MALLINCKRODT INC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Tablets	7.5 mg/325 mg	➤ Subscribe	2014-04-03

Premature patent expirations for MALLINCKRODT INC

Expiration due to failure to pay maintenance fee

Patent Number	Expiration Date
➤ Sign Up	➤ Sign Up

International Patents for Mallinckrodt Inc Drugs

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Estimated Expiration
Australia	3989301	➤ Sign Up
South Korea	20030023876	➤ Sign Up
Mexico	2010009990	➤ Sign Up
European Patent Office	2654727	➤ Sign Up
Australia	2001239893	➤ Sign Up
Canada	2409552	➤ Sign Up
World Intellectual Property Organization (WIPO)	0197783	➤ Sign Up
Country	Document Number	Estimated Expiration

Supplementary Protection Certificates for Mallinckrodt Inc Drugs

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C0013	France	➤ Sign Up	PRODUCT NAME: DASABUVIR OU UN SEL DE CELUI-CI, NOTAMMENT LE SEL DE SODIUM; REGISTRATION NO/DATE: EU/1/14/983 20150119
90064-1	Sweden	➤ Sign Up	PRODUCT NAME: SIMEPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
C0022	France	➤ Sign Up	PRODUCT NAME: MONTELUKAST SODIUM; REGISTRATION NO/DATE IN FRANCE: NL 23 133 DU 19980320; REGISTRATION NO/DATE AT EEC: 13 651 DU 19970825
C/GB08/036	United Kingdom	➤ Sign Up	PRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425
595	Luxembourg	➤ Sign Up	PRODUCT NAME: SIMEPREVIR, OU L UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, INCLUANT SIMEPREVIR SODIUM. FIRST REGISTRATION: 20140516
C0041	France	➤ Sign Up	PRODUCT NAME: ERTAPENEM SODIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418
C0108	Belgium	➤ Sign Up	PRODUCT NAME: MANGAFODIPIR TRISODIUM (ANHYDROUS) CORRESP. MANGAFODIPIR; REGISTRATION NO/DATE: EU/1/97/040/001 19970522
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca

Queensland Health

Daiichi Sankyo

Baxter

Express Scripts

Citi

Fuji

QuintilesIMS

Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.